WO2009134010A2 - Pharmaceutical composition using herbal extract for prevention and treatment of obesity and metabolic disorders - Google Patents

Abstract

The present invention relates to a composition using composite herbal extracts for prevention and treatment of obesity and metabolic disorder. More specifically, the invention provides a composition containing Evodiae Fructus, Imperatae Rhizoma, and Citrus unshiu Markovich for prevention and treatment of obesity and metabolic syndromes or syndrome X.

Description

[Revision according to Rule 26.06.10.2009] Composition for the prevention or treatment of obesity and metabolic syndrome using complex herbal medicine

The present invention relates to a composition for preventing or treating obesity and metabolic syndrome using a composite herbal medicine.

Obesity was already prescribed as a disease in 1996 by the World Health Organization. About 150 million people worldwide have experienced obesity, a health risk factor, and since obesity is directly related to various adult diseases, there is an urgent need for treatment for obesity. In addition, the market size of obesity drugs is on the rise due to the improvement of economic level and increased interest in appearance.

The market for obesity drugs was about $ 1.3 billion in 2000 and is growing at an annual average of nearly 20%. There are more than 10 kinds of obesity treatments currently in final stage of clinical trials or waiting for FDA's approval.Jenical and Reductil have already been approved by the US FDA as well as introduced in Korea and are rapidly spreading. [Health Industry Technology Trend, 2001 winter].

Obesity is a problem that obesity itself causes constipation, indigestion, gastrointestinal disorders due to the abdominal pressure by the fat tissue, as well as the risk factors of many adult diseases. Obesity is known to cause all kinds of complications such as cancer, arteriosclerosis, heart disease, high blood pressure, diabetes and other complications, and in 1996, the World Health Organization (WHO) warned that obesity is a disease that needs treatment. A study of 750,000 people reported a 1.9-fold increase in mortality in men and women over 40% above average body weight compared to those of normal weight. In particular, in recent years, such obesity has been found to be the cause of the development of the so-called metabolic syndrome (X-syndrome), which is considered to be a pre-development stage of diabetes and hypertension, and its prevalence is found to be one quarter of the world's population. Its seriousness is growing.

Metabolic syndrome is characterized by insulin resistance, abdominal obesity, hyperlipidemia, hypertension, hyperglycemia, and is a particularly frequent symptom in obese people. The WHO warned the American Medical Association (JAMA) that anyone with a metabolic syndrome is more likely to become a diabetic, stroke or heart disease patient.

Metabolic syndrome patients are those who overlap three or more of the following five symptoms.

(1) Waist circumference ------- (Male) More than 100 cm (Female) More than 88 cm

(2) Blood pressure ----------- 135/80 mmHg or more

(3) blood sugar ----------- 110 (fasting) mg / or more

(4) Neutral lipid ------- 150 mg / dl or more

(5) HDL levels ----- (male) 40 mg / dl or less (female) 50 mg / dl or less

It is clear that the metabolic syndrome patients are ultimately derived from obesity. At this time, the management of obesity is more important in relation to the occurrence of metabolic syndrome patients, which is a pre-development stage of most adult diseases.

Obesity is a condition where excess fat is accumulated in the body, and fat is accumulated in the body due to excessive intake of sugar (carbohydrate) or excessive intake of fat. The mechanism of reaching obesity is that by over-ingesting the sugar, the sugar in the food is digested and becomes monosaccharide and absorbed into the body through the small intestine.Increased blood sugar increases insulin secreted by the stimulus and acts on fat cells to release the monosaccharide in the blood. Fat cells are taken in and converted into fat. In addition, fat, which is the highest calorie among food ingredients, is broken down by pancreatic lipase and absorbed through the small intestine, resulting in an increase in stored calories due to excess calories. That is, obesity is caused by excess fat intake.

Therefore, research on various anti-obesity agents is currently being conducted based on the idea of generating anti-obesity effects by inhibiting a part of certain pathways leading to obesity.

Glycolytic digestion, which inhibits the path to obesity due to excessive intake of glucose, suppressed the rise in blood sugar, or suppressed the adsorption of cholic acid, which inhibits the path to obesity, by inhibiting the absorption of monosaccharides or by excessive intake of fat, cholesterol lowering It is thought that obesity can be prevented and improved by the action, the blood triglyceride lowering action, or the lipase inhibitory action, and the research on the pharmaceutical component which has these actions is continuing.

Sudden postprandial blood sugar rise and excessive insulin secretion due to excessive intake of carbohydrates (sugars) can lead to diabetes or hyperlipidemia in addition to obesity [pharmacology and treatment Vol. 19, No. 10 Oct. 274, 1991] is known to inhibit and improve diabetes or hyperlipidemia by inhibiting glycolysis digestive enzymes. Therefore, glycosylated digestive enzyme inhibitors, monosaccharide absorption inhibitors, or blood glucose elevation inhibitors are considered to be useful as antidiabetic agents, antihyperlipidemic agents, or antiarteriosclerosis agents. Glycolytic digestive enzyme inhibitors currently being used as drugs include acarbose (Acarbose, Bayer Pharmaceutical Co., Ltd.) and Bogriboose (AO-128, Daeda Pharmaceutical Co., Ltd.), a post-prandial hyperglycemic improver. These animals have been shown to have an inhibitory effect on post-prandial blood sugar levels in animal and clinical trials. Exp. Med.vol. 175, 87 (1979), Japanese Society for Agricultural Chemistry vol. 63, 217 (1989), New Current vol. 6, 2 (1995). In addition, methods of inhibiting the path leading to obesity by ingesting fat (triglyceride) include cholic acid adsorption excretion, cholesterol lowering, blood triglyceride lowering, lipase inhibition, and the like. Drugs with cholic acid excretion include cholstyramine, a hypercholesterolemic drug, which is an anion exchange resin. By oral administration of the anion exchange resin, the anion exchange resin is circulated in the gut [Makino Isaora, Taisha, vol. 24, No. 8, 685-692, 1987] adsorption and fixation of the intestinal cholic acid prevents resorption of the cholic acid, promotes the conversion of cholesterol into the cholic acid in the liver, and consequently lowers the blood cholesterol concentration. However, the usage of cholestyramine is that 9 g is taken in 100 mL of water, so the dose is very high, and when taken, the rough unpleasant texture of the resin remains in the mouth, making it very difficult for the patient to take it. There was a problem.

As described above, a number of chemical synthetic compounds having respective actions have been reported and used as medicines, but they have a problem in that they have a high dose or are unpleasant at the time of taking them, and because they are chemical synthetic compounds, the subjects may not In some cases, safety was anxiety.

Therefore, due to such safety issues, product development using natural products at home and abroad is increasing.

In particular, Cois semen, Dioscoreae rhizoma, Gilkyung (Platycodi radix, bellflower), Schizandrae fructus, Citrus unshiu Markovich, Aloe vera, Adenophorae radix (Sasam), etc. Some anti-obesity drugs have been developed, which consist of extracts of several herbal drugs or mixtures. In addition, Korean Patent Publication No. 2007-0042755 discloses a composition for inhibiting or treating obesity using a ginseng component, and in KR0733336, a composition for preventing or treating obesity or hyperlipidemia using a root is registered.

However, in the case of such natural-derived products so far known, the material is very expensive, many times to consume a large amount to obtain a proper effect, or the effect to prevent obesity and prevent hyperlipidemia in many cases.

Therefore, there is a need to research and develop a new herbal composition that can be easily obtained even though it is a natural material and can have a more complex effect.

In addition, the applicant of the patent has registered a patent for the treatment of obesity using the herbal medicines such as white hair roots and the inhibitory composition (or extract) through the registration publications KR0573590, KR0573591 and KR0573592, but further research has been found to be superior in abdominal fat reduction. It is a new invention of the composition of the present invention to effect.

Therefore, the present inventors confirmed that the complex extracts of the herbal medicines, Osuyu, Baek-geun-geun and Cheongpi, were effective in inhibiting weight gain, abdominal fat reduction, and triglyceride and blood glucose levels through animal experiments. In addition, in vitro tests confirmed the effect of increasing the activity of AMPK enzyme, a biomarker associated with obesity and diabetes, and also confirmed the effect of increasing glucose uptake in myocytes and adipocytes.

Accordingly, an object of the present invention is to provide a composition for the prevention and treatment of obesity and metabolic syndrome, which contains a complex extract of Evodiamine Fructus , Cerrus Unshiu Markovich and White Hair Root (Imperatae Rhizoma) as an active ingredient.

In addition, the present invention has another object to provide a health food containing the complex extract.

An object of the present invention is to provide a composition for the prevention and treatment of obesity and metabolic syndrome, which contains a complex extract of Evodiamine Fructus , Cerrus Unshiu Markovich and White Root Muscle (Imperatae Rhizoma) as an active ingredient.

In addition, it includes a health food containing the complex extract.

The complex extract according to the present invention promotes the expression of genes related to the prevention and treatment of obesity and metabolic syndrome in cells, and has a very good weight gain inhibitory effect and high levels of triglycerides and blood glucose in blood in mice fed high fat diet. Improves glucose uptake in myocytes and adipocytes.

Figure 1 shows the combined effect of the present invention AMPK enzyme activity using the obese animal model.

2 shows body weight changes of experimental mice for 10 weeks.

Figure 3 is a measure of the increase in glucose uptake capacity in the muscle cells of the complex extract according to the present invention.

Figure 4 measures the increase in glucose uptake capacity in mast cells of the complex extract according to the present invention.

Hereinafter, the present invention will be described in more detail.

The present invention for achieving the above object, in the composition for the prevention and treatment of obesity and metabolic syndrome containing a complex extract of sorghum ( Evodiamine Fructus ), cheongpi (Citrus Unshiu Markovich) and white hair root (Imperatae Rhizoma) as an active ingredient It is about.

In the present invention, it is preferable to mix 0.1 ~ 10 parts by weight and 0.1 ~ 30 parts by weight of the white hair root extract with respect to 1.0 parts by weight of sewage extract to use the composite extract as an active ingredient.

The complex extract according to the present invention may be prepared by first obtaining a method such as cold water extraction, hot water extraction or solvent extraction according to a conventional method, drying, and then mixing in the above ratio. In this case, each herbal may be extracted in different ways. For example, it can be manufactured by the following method.

First, each of the sewage, skin and white hair roots that have been screened and cut to the appropriate size are prepared. At this time, 0.1 to 10 parts by weight of cheongpi, 0.1 to 30 parts by weight of white hair root are used based on 1 part by weight of sewage oil. 10 to 100 times the amount of each aqueous solution of alcohol is added, extraction is performed for 4 to 8 hours at 70 to 100 ° C., followed by rapid freezing for 10 to 20 hours at -50 to -30 ° C., and 30 to 30 at a pressure of 0.1 to 0.5 Torr. Vacuum dried for 40 hours and then ground to prepare dry powder. Subsequently, the dry powder of each herbal medicine is mixed by the said ratio, and the composite extract powder which concerns on this invention is obtained. Of course, the solid content of each herbal extract before drying may be investigated in advance, and then the extract may be mixed so as to have the above ratio, and then dried in a batch to obtain a composite extract powder according to the present invention.

Meanwhile, the composite extract according to the present invention may be obtained by first mixing each herbal dry matter of a calculated ratio so as to finally be the above ratio, and then extracting them in a batch. To this end, a mixture of 1.0 parts by weight of dried sewage extract, 0.1 to 10 parts by weight of dried skin extract and 0.1 to 30 parts by weight of dried white hair root extract is prepared by a method such as cold water extraction, hot water extraction or solvent extraction according to a conventional method. After extraction, the mixture may be used as it is by filtration, concentrated to use, or lyophilized to be used as powder. For example, it can be manufactured by the following method. First, the sewage, skin and white hair roots, which have been selected and trimmed to an appropriate size, are mixed in accordance with the mixing ratio. 10-100 times the amount of aqueous alcohol solution was added to the mixture, extraction was performed at 70-100 ° C. for 4-8 hours, and then rapidly frozen at -50 ° -30 ° C. for 10-20 hours, and 30-40 at a pressure of 0.1-0.5 Torr. Drying in vacuo for time and then pulverizing yields the composite extract powder according to the present invention.

As a result of many experiments and studies, the inventors have confirmed that the best herbal composition is obtained only when the content ratio is as described above.

In addition, the complex extract according to the present invention can be seen in the preparation examples and examples below, by increasing the cellular uptake of AMPK at the same time to increase the intracellular AMPK activity, a conventional conventional herbal medicine or commercial drugs for the treatment and inhibition of obesity It is much better and safer than that.

Therefore, the complex extract of the present invention can be prepared as a pharmaceutical.

The complex extract of the present invention can be administered to mammals such as mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.

In addition, the present invention provides a health functional food comprising the composition and a food acceptable food supplement additive exhibiting a prophylactic and therapeutic effect of obesity and metabolic syndrome. Examples of the food to which the complex extract can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.

In addition, the present invention includes a health food for improving obesity and metabolic syndrome containing a complex extract as an active ingredient. In addition to the complex extract, the health food may contain various supplemental herbal medicines, vitamins, minerals, dietary fiber, and other medicinal-food supplements (eg, excipients, enhancers, coatings, etc.).

It may also be added to foods or beverages for the purpose of preventing and treating obesity and metabolic syndrome. At this time, the amount of the complex extract in the food or beverage, in the case of the health food of the present invention can generally be added to 0.0001 to 100% by weight, preferably 80% by weight or less of the total food weight, 100 ml to the health beverage composition It can be added in a ratio of 0.0001 to 10 g, preferably 5.0 g or less as a reference.

Hereinafter, the present invention will be described in more detail in Examples and Application Examples. The following examples are merely illustrative of the present invention in detail, and thus, the nature of the technical idea of the present invention is not changed or reduced in scope. It will be apparent to those skilled in the art that various embodiments and applications not shown in the following examples are possible.

Preparation Example: Preparation of Complex Extract

(1) A 10-fold weight of 70% aqueous ethanol solution was mixed with 1 Kg of dried sewage, white hair root and skin skin, which were previously screened and cut into appropriate sizes, and then heated and subjected to primary extraction at 85 ° C. for 6 hours. Thereafter, the primary filtrate was collected separately by filtration, and the filtered crude drug was further mixed with an aqueous 10% weight 70% ethanol aqueous solution, followed by heating to carry out secondary extraction at 85 ° C. for 6 hours. Subsequently, the resultant was filtered to obtain a secondary filtrate, followed by rapid freezing with the primary filtrate at 70 ° C. for 12 hours, vacuum drying for at least 36 hours under a pressure of 0.23 Torr or less, and then grinding to obtain respective dry powders.

The obtained sewage oil, white hair root and dermis extract powder was mixed with 1 part by weight of white hair root extract and 3 parts by weight of dermis extract based on 1 part by weight of sewage extract to obtain a composite extract powder (composite extract) of the present invention.

(2) The extraction efficiency of each herbal medicine was analyzed beforehand, and then each dry herbal medicine was mixed in the final extract. That is, dry sewage oil, white hair root and green skin, which were previously screened and cut to an appropriate size, were mixed, a 10-fold weight of 70% ethanol aqueous solution was poured, and heated to carry out primary extraction at 85 ° C. for 6 hours. Thereafter, the primary filtrate was collected separately by filtration, and the filtered crude drug was further mixed with an aqueous 10% weight 70% ethanol aqueous solution, followed by heating to carry out secondary extraction at 85 ° C. for 6 hours. Subsequently, the resultant was filtered to obtain a secondary filtrate, followed by rapid freezing with the primary filtrate at 70 ° C. for 12 hours, vacuum drying for at least 36 hours under a pressure of 0.23 Torr or less, and then grinding to obtain respective dry powders.

(3) As a result of analysis of various indicator components and in vitro and in vivo experiments, the herbal compositions according to the present invention prepared by the two methods were identified as the same. Therefore, in the following experiment, the thing by two methods was used for an Example without distinguishing.

Example 1 Determination of AMPK Enzyme Activity of Complex Extracts

The cells were treated with the composite extract of the preparation, and then AMPK activity was examined over time. Activation of the AMPK enzyme increases glucose uptake, inhibits fatty acid synthesis, and induces fatty acid oxidation, and thus this experiment can confirm the prophylaxis or treatment of obesity and metabolic syndrome of the complex extract of the present invention.

As can be seen in Figure 1, in the composite extract of the present invention can be seen to significantly increase the AMPK enzyme expression compared to the positive control AICAR.

Example 2 Screening of the Effects of Complex Extracts on Weight Gain in Animal Models and Their Effects on Fat Accumulation and Plasma Fat and Sugar

(1) Experimental animals purchased 20 to 25 g of 6-week-old C57BL / 6 mice from the central laboratory animals, and allowed them to freely feed and water in the animal room, and after one week, divided them into four groups as follows. Regular Diet (RD) and 45% High Fat Diet (HFD). Six weeks later, the mice were separated by weight, and 5 mice were placed in cages so that an average of 36 to 37 g of HFD was put into two cages (10 mice). The average diet weight was 27 g. High-fat diet mice were orally administered with the complex extract of the present invention for 10 weeks every day to observe the weight change and intake of the mice.

RD: normal diet control diet fed a normal diet, HFD: high fat diet control group fed 45% high fat diet, HFD + complex extract: high fat diet + complex extract (500 mg / kg), HFD + sibutramine: high fat diet Used as a positive control with this + sibutramine (2 mg / kg).

(2) To determine the therapeutic effect of metabolic syndrome (medibolic syndrome) for 6 weeks in a high fat diet mouse fat (diet induced obesity) in the mouse (diet induced obesity) of the compound extract of the present invention at a constant time of 500 mg / kg daily Was administered orally with high fat diet for 10 weeks. Body weights were measured twice a week and food intake was measured once every two days. Ten weeks later, blood was collected from the eyeballs of the mice, and the blood was collected, each tissue of the mouse was extracted, weighed, and used in the assay.

(3) Sampling and Blood Indicator Analysis

At the last sacrifice, blood was collected from the orbital vein, and each tissue was extracted and weighed for analysis. For blood index analysis, blood collection was performed using plasma after centrifugation of whole blood obtained from the orbital vein for 30 minutes at 1,500 rpm after fasting on the previous day (8-10 hours), and astaxet triglycerides, glucose and cholesterol. (cholesterol) kits were purchased and measured with an ELISA reader.

(4) experimental results

① weight change

Figure 2 is the result of comparing the weight change pattern between each group for 10 weeks. As shown in FIG. 2, when the sample was administered after inducing obesity for 6 weeks with a high fat diet, the body weight of the mice was temporarily decreased until 2 weeks. This may be due to the stress of the mouse by oral administration. Body weight gained again from 3 weeks, and significantly increased weight suppression effect in group administered 500 mg / kg of complex extract at 5 weeks compared with control group. This effect lasted up to 10 weeks. Compared with the groups at 10 weeks, the body weight of the high-fat diet group (HFD) increased to 46.5 ± 1.5 compared to the normal diet group (RD, 29.5 ± 1.2), whereas the complex extract group was 41.3 at the 500 mg / kg dose, respectively. ± 1.7. Meanwhile, the weight of the sibutramine-treated group, which was a positive control group, was 43.3 ± 1.7, which was lower than that of the high-fat diet. As a result of the present experiment, the complex extract of the present invention was found to have better activity in weight inhibition than the positive control group.

② Organization weight analysis

In Table 1, 10 weeks after the abdominal fat (liver), liver (liver), kidney (kidney), spleen (spleen), brain (brain), muscles (hind muscles), etc. tissues were extracted to double fat, liver This is a result of measuring the weight of the kidney, height and spleen.

Compared to the normal diet (RD), the high fat diet (HFD) significantly increased abdominal fat, significantly increased liver and kidney weights, and the weight of other organs was not significantly changed. In the case of adipose tissue, the high-fat diet group was 4.5 ± 0.5, whereas the combined extracts showed 3.2 ± 0.4 of abdominal fat reduction on average by 30%.

Table 1

③ blood analysis

The following Table 2 shows the plasma-derived plasma of the mice obtained from orbital vein after fasting overnight (8 hours) after oral administration of the complex extract to diet-induced obesity for 10 weeks. Blood glucose and cholesterol were analyzed. In the case of triglycerides, the high-fat diet control group (HFD) increased to 142.8 ± 11.4 mg / dL compared to the general diet group (RD), whereas the complex extract group was 123.4 ± 12.2 at 500 mg / kg dose compared to the high-fat diet control group. Neutral lipid reduction effect was shown. In the case of blood glucose, the high-fat diet control group (HFD) increased 255.6 ± 30.1 mg / dL compared to the general diet group (RD), whereas the complex extract group showed 204.1 ± 14.5 mg / dL at 500 mg / kg dose. Compared with this control group, the blood glucose reduction effect was shown. In the case of triglyceride and blood glucose, the high fat diet was more effective than the control group, but the cholesterol was less correlated with the body weight.

TABLE 2

As a result, the composite extract according to the present invention was found to be useful for the reduction of neutral lipid and blood glucose levels as well as the weight loss effect.

Example 3 Investigation of Glucose Absorption Capacity in Myofas and Adipocytes of the Complex Extract

(1) Investigation of the glucose uptake effect of C2C12 myocytes and 3T3 L1 adipocytes in the complex extract according to the present invention to investigate the possibility of development as a therapeutic agent for obesity and diabetes.

(2) Effect of Increasing Glucose Uptake of Composition on C2C12 Myocytes

The complex extract of the present invention was dissolved in water and treated with different concentrations of cells for 24 hours, followed by MTT analysis to select the highest cytotoxicity (cytotoxic) concentration and glucose absorption ability in C2C12 myocytes (Fig. 3). The complex extract of the present invention was observed to increase glucose uptake better than insulin at a 100 μg / mL dose, which is considered to be effective for glucose uptake.

(3) Glucose uptake effect of composition in 3T3 L1 adipocytes

The composite extract of the present invention was dissolved in water to investigate the effect on glucose uptake using 3T3L1 adipocytes at low concentrations of cytotoxicity (FIG. 4). The complex extract of the present invention was observed to increase glucose uptake to a similar extent to 100 nM insulin, indicating a good glucose uptake effect.

In conclusion, the composite extract according to the present invention confirmed the effect of inhibiting weight gain and improving neutral lipid and blood glucose levels through animal experiments and enhancing the activity of AMPK enzyme, a biomarker related to the prevention or treatment of obesity and metabolic syndrome, through in vitro tests. It was confirmed that the effect of increasing the glucose uptake capacity in myocytes and adipocytes.

Thereby, the composite extract according to the present invention was confirmed that it can be usefully applied to the treatment and prevention of diseases associated with obesity and metabolic syndrome.

Formulation Example 1 Preparation of Injection

(1) Complex extract of Preparation Example .................. 100 mg

pH adjuster ...

The above ingredients were mixed and prepared in a conventional manner, and then injected into a 2 ml ampoule and sterilized to prepare an injection.

Formulation Example 2: Preparation of Tablet

(1) Complex Extract of Preparation Example ......................................... 50 mg

Lactose ............... 125 mg

Microcrystalline cellulose ... 75 mg

Magnesium Stearate ...............

The tablets were prepared by mixing the above components and tableting according to a conventional method for producing tablets.

Formulation Example 3 Preparation of Capsule

(1) Complex extract of Preparation Example .................. 100 mg

Lactose ............... 125 mg

Starch ............... 125 mg

Talc ..............................

Magnesium Stearate ...............

The capsules were prepared by mixing the above components and filling the capsules according to a conventional method for preparing capsules.

Formulation Example 4 Preparation of Liquid

(1) Complex extract of preparation example ..... 1000 mg

Min .......................................... 20 g

Isomerized sugar ......................................... 20 g

Lemon Flavor ......................

Purified water was added to adjust the total volume to 1000 ml. According to the conventional method for preparing a liquid, the above components were mixed to prepare a liquid.

Formulation Example 5 Preparation of Health Functional Food

(1) Complex extract of preparation example ......................... 100 mg

Vitamin A (0.275 mg as Retinyl Palmitate) ............. 500 IU

DL-alpha-tocopherol ......................................... 20 mg

Vitamin B1 Nitrate ......................................... 1.5 mg

Vitamin B2 ..................... 1.8 mg

Pyridoxine Hydrochloride ............................................... 2 mg

Vitamin B12 ... .2 μg

Biotin ... ..0.1 mg

Nicotinic acid amide ......................................... 5 mg

Folic Acid ... .... 0.1 mg

Calcium Pantothenate ......................................................... 5 Mg

Vitamin C ... ..50 mg

Glycerin ginseng calcium (4.76 mg as calcium) ... 25 mg

Iron sulphate (5.0 mg as iron) ... 15.45 mg

Zinc sulfate (1.0 mg as zinc) ........................ 2.74 mg

Copper sulfate (0.5 mg as copper) ..

Manganese sulfate (0.5 mg as manganese) ........................ 1.54 mg

Although the composition ratio of the complex extract of the present invention, vitamins and minerals, etc. are mixed with the components suitable for the health functional food in a preferred embodiment, the composition ratio may be arbitrarily modified, and according to the conventional health functional food manufacturing method After mixing the above components to prepare a granule, it can be used for preparing a nutraceutical composition according to a conventional method.

Formulation Example 6 Preparation of Healthy Drinks

(1) Complex extract of the preparation example ....... 500 mg

Citric Acid ......................................... 1000 mg

Oligosaccharide ... 20 mg

Taurine ........................... 100 mg

Purified water was added to adjust the total volume to 900 ml. It is prepared according to a conventional healthy beverage manufacturing method.

Although the composition ratio is a composition that is relatively suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Claims (5)

1. A composition for the prevention and treatment of obesity and metabolic syndrome, comprising a complex extract of Evodiamine Fructus , Citrus Unshiu Markovich and White Root (Imperatae Rhizoma) as an active ingredient.
2. According to claim 1, wherein the complex extract is based on 1.0 parts by weight of sewage oil extract, 0.1 ~ 10 parts by weight of the extract and 0.1 ~ 30 parts by weight of white hair root extract, characterized in that the composition for the prevention and treatment of obesity and metabolic syndrome.
3. The composition according to claim 1, wherein the composition has a prophylactic and therapeutic effect on obesity and metabolic syndrome according to the enhancement of intracellular AMPK activity and glucose uptake.
4. Health food for improving obesity and metabolic syndrome, characterized in that it contains a complex extract of Evodiamine Fructus , Citrus Unshiu Markovich, and White Root (Imperatae Rhizoma) as an active ingredient.
5. According to claim 4, wherein the complex extract is based on 1.0 parts by weight of sewage oil extract, health food, characterized in that the mixture 0.1 ~ 10 parts by weight and 0.1 ~ 30 parts by weight of white hair root extract.

Images